(Q41102136)

26 September 2017

1 reference

title

Angiotensin II receptor antagonists: the prototype losartan (English)

1 reference

26 September 2017

K L Schaefer

1

1 reference

26 September 2017

J A Porter

series ordinal

2

1 reference

26 September 2017

language of work or name

English

0 references

publication date

1 June 1996

1 reference

Annals of Pharmacotherapy

26 September 2017

published in

1 reference

26 September 2017

volume

30

1 reference

26 September 2017

issue

6

1 reference

26 September 2017

page(s)

625-636

1 reference

Angiotensin II receptor blockade: an innovative approach to cardiovascular pharmacotherapy

26 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000611

The clinical potential of renin inhibitors and angiotensin antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000611

Angiotensin II receptor antagonists: a new approach to blockade of the renin-angiotensin system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000611

Renin inhibition: a new approach to cardiovascular therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000611

The expanding role of angiotensin converting enzyme inhibitors in the management of hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000611

Angiotensin-converting enzyme inhibitors and cough: a prospective evaluation in hypertension and in congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000611

Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000611

The positive association of cough with angiotensin-converting enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000611

Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000611

Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000611

Nonpeptide angiotensin II receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000611

Hypotensive activity of TCV-116, a newly developed angiotensin II receptor antagonist, in spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000611

Pharmacological profile of GR117289 in vitro: a novel, potent and specific non-peptide angiotensin AT1 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000611

Characterization of BIBS 39 and BIBS 222: two new nonpeptide angiotensin II receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000611

DuP 753 is a specific antagonist for the angiotensin receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000611

Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000611

Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000611

Losartan potassium, a nonpeptide antagonist of angiotensin II, chronically administered p.o. does not readily cross the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000611

Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000611

Proto-oncogenes and cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000611

Effects of losartan, a nonpeptide angiotensin II receptor antagonist, on cardiac hypertrophy and the tissue angiotensin II content in spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000611

Neurohumoral control mechanisms in congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000611

Enalapril in congestive heart failure: acute and chronic invasive hemodynamic evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000611

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000611

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000611

Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000611

Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000611

Angioedema induced by the angiotensin II blocker losartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000611

Importance of the renin-angiotensin-aldosterone system (RAS) in the physiology and pathology of hypertension. An overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000611

10.1177/106002809603000611

21 January 2018

Identifiers

DOI

0 references

1 reference